Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC)
Autore:
Ardizzoni, A; Antonelli, G; Grossi, F; Tixi, L; Cafferata, M; Rosso, R;
Indirizzi:
Ist Nazl Ric Canc, Dept Med Oncol, I-16132 Genoa, Italy Ist Nazl Ric CancGenoa Italy I-16132 pt Med Oncol, I-16132 Genoa, Italy
Titolo Testata:
ANNALS OF ONCOLOGY
, volume: 10, anno: 1999, supplemento:, 5
pagine: 13 - 17
SICI:
0923-7534(1999)10:<13:TCOEAC>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE CISPLATIN; PHASE-II; RANDOMIZED TRIAL; ORAL ETOPOSIDE; ACTIVE REGIMENS; CLINICAL-TRIAL; ONCOLOGY GROUP; WORKING PARTY; CHEMOTHERAPY; CARCINOMA;
Keywords:
advanced disease; chemotherapy; cisplatin; etoposide; non-small-cell lung cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Ardizzoni, A Ist Nazl Ric Canc, Dept Med Oncol, Largo R Benzi 10, I-16132 Genoa, Italy Ist Nazl Ric Canc Largo R Benzi 10 Genoa Italy I-16132 Italy
Citazione:
A. Ardizzoni et al., "The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC)", ANN ONCOL, 10, 1999, pp. 13-17

Abstract

The role of chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) has been a subject of debate for many years. Only recently, cisplatin-based combination chemotherapy has been demonstrated to yield a small but definite survival benefit and to improve symptoms, performance status and quality of life in a substantial proportion of advanced NSCLC patients. The cisplatin-etoposide (PE) regimen was developed in the early 1980s and has been one of the standard chemotherapy programs most extensively used in the clinical practice until a few years ago. More recently, several randomized trials have compared the efficacy of new cisplatin-containing combination chemotherapies including Paclitaxel or Gemcitabine with that of PE or PE-like regimens. Preliminary results are encouraging, indicating a small benefit in favor of the last generation of regimens which might thereforereplace PE as 'gold standards' in the treatment of advanced NSCLC. However, the costs of these last generation regimens is higher and the entity of the benefit small. Therefore, PE chemotherapy can still be an option in selected situations.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 08:55:38